BioSpace News Archive

Philogen S.p.A. is pleased to announce a publication describing the construction of a DNA-encoded chemical library that was successfully screened against multiple protein targets, yielding potent and selective small molecule binders against disease-relevant antigens.

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that its FDA-authorized Nerivio® prescribed wearable for the acute treatment of migraine is now eligible for insurance coverage through the UpScript direct-to-patient telemedicine platform.

Akers Biosciences, Inc., announced that its proposed merger partner MyMD Pharmaceuticals, Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board.

The American College of Radiology® (ACR®) has brought together the full power of its world-class informatics and clinical research resources to launch the innovative ACR National Clinical Imaging Research Registry™ (ANCIRR™).

Overall, the 3rd PRO found similar or comparable efficacy and yield results evaluating MustGrow’s natural mustard-derived biological products versus the widely-used synthetic fumigation chemical, Chloropicrin.

Mr. McFadden most recently served as Chief Commercial Officer of MPower Health, a privately held orthopedic healthcare services company focused on value-based care solutions and interoperative neuromonitoring clinical services.

Embark Veterinary, a leader in dog genetics, announced that the uniquely spotted coat of German Shorthair Pointers, Australian Cattle Dogs, and other breeds known as “roaning” is strongly associated with a genomic region on chromosome 38 and likely regulated by the usherin gene.

Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces that David Fischel, Chairman and CEO, will serve as the keynote speaker at the Robotic Surgery & Enabling Technologies Virtual Summit 2021.

SOTIO, a clinical stage immuno-oncology company owned by PPF Group,announced new preclinical data of its antibody-drug conjugate (ADC), SOT102 (formerly SO-N102), for the treatment of solid tumors in a virtual poster presentation at the 2021 American Association of Cancer Research (AACR) Annual Meeting.

Clinical studies support effectiveness and safety profile for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older